Amlodipine: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "==Sources==" to "==References==") |
Neil.m.young (talk | contribs) (Text replacement - "* " to "*") |
||
| Line 7: | Line 7: | ||
#HTN | #HTN | ||
#* 5-10mg PO qDaily | #*5-10mg PO qDaily | ||
#* Start: 5mg PO qDaily for intial antihypertesnive, do 2.5 if elderly or 2nd line drug | #*Start: 5mg PO qDaily for intial antihypertesnive, do 2.5 if elderly or 2nd line drug | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
#HTN | #HTN | ||
#* 2.5-5mg PO qDaily | #*2.5-5mg PO qDaily | ||
==Special Populations== | ==Special Populations== | ||
Revision as of 04:02, 5 July 2016
General
- Type: Anti-Hypoertensive (dihydropyridine-CCB)
- Dosage Forms: 2.5, 5, 10mg
- Common Trade Names: Norvasc
Adult Dosing
- HTN
- 5-10mg PO qDaily
- Start: 5mg PO qDaily for intial antihypertesnive, do 2.5 if elderly or 2nd line drug
Pediatric Dosing
- HTN
- 2.5-5mg PO qDaily
Special Populations
- Pregnancy Rating: C
- Lactation: Safety Unknown
- Renal Dosing
- Adult: no adjustment
- Pediatric: no adjustment
- Hepatic Dosing
- Adult: Start at 2.5mg qDaily
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Severe CAD, AS, CHF
- Re-dose/Caution: Elderly/Hepatic Impairment
Adverse Reactions
Serious
- Angina, MI, Hypotension, Hepatitis, Erythema multiforme
Common
- Peripheral edema, fatigue, palpitations, dizziness, nausea, flushing, eczematous eruptions
Pharmacology
- Half-life: 30-50h
- Metabolism: liver extensively; CYP450: 3A4
- Excretion: urine 59-62% (5-10% unchanged), bile/feces 20-25%
- Mechanism of Action: CCB-dihydropyridine